Artielle, QSV Sign cGMP Contract for MS Drug

QSV Biologics, Ltd. and Artielle ImmunoTherapeutics, Inc. have signed a contract for the process development and cGMP manufacturing of RTL 1000 for multiple sclerosis. QSV will be responsible for technology transfer, process development and cGMP manufacture of Phase II/III trial material. RTL 1000, licensed by Artielle from Oregon Health & Science University, is a Recombinant T cell receptor Ligand (RTL) that can treat a wide range of autoimmune diseases.

Graeme Macaloney Ph.D., PEng, QSV president and chief executive officer said, “The combination of novel class of molecules, experienced management team, and quality investors behind Artielle ensure the best possible opportunity for successfully bringing these much needed autoimmune disease therapies to patients. We are proud to be providing the manufacture of this important MS therapeutic.”